Valentina Perri

Pubblicazioni

Titolo Pubblicato in Anno
Evaluation of baff, april and cd40l in ocrelizumab-treated pwms and infectious risk BIOLOGY 2023
Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study MULTIPLE SCLEROSIS JOURNAL, EXPERIMENTAL, TRANSLATIONAL AND CLINICAL 2022
Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine FRONTIERS IN IMMUNOLOGY 2022
Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia FRONTIERS IN IMMUNOLOGY 2021
Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia. A retrospective cohort study PLOS ONE 2021
Early IgG / IgA response in hospitalized COVID-19 patients is associated with a less severe disease DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE 2021
Chest computed tomography score, cycle threshold values and secondary infection in predicting COVID-19 mortality NEW MICROBIOLOGICA 2021
JCPyV NCCR analysis in PML patients with different risk factors: Exploring common rearrangements as essential changes for neuropathogenesis VIROLOGY JOURNAL 2020
The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia JOURNAL OF NEUROIMMUNOLOGY 2020
Major reduction of NKT cells in patients with severe COVID-19 pneumonia CLINICAL IMMUNOLOGY 2020

ERC

  • LS5_15
  • LS6
  • LS6_1
  • LS6_2
  • LS6_3
  • LS6_4
  • LS6_6
  • LS6_7
  • LS6_8

Keywords

immunology/infectious diseases
autoimmune diseases
herpes simplex virus
Neuroinflammation
flow-cytometry
molecular biology

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma